Jasper Hellweg
Stock Analyst at Argus Research
(3.51)
# 830
Out of 4,784 analysts
88
Total ratings
53.52%
Success rate
17.97%
Average return
Main Sectors:
Stocks Rated by Jasper Hellweg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $360 → $400 | $306.97 | +30.31% | 7 | Oct 31, 2024 | |
| ILMN Illumina | Upgrades: Buy | $150 | $80.00 | +87.50% | 7 | Aug 28, 2024 | |
| SNY Sanofi | Maintains: Buy | $55 → $60 | $55.82 | +7.49% | 2 | Jul 26, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,060 → $1,170 | $637.36 | +83.57% | 9 | Jun 25, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $465 → $550 | $492.69 | +11.63% | 7 | Jun 17, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $80 → $85 | $73.79 | +15.19% | 3 | May 30, 2024 | |
| NVO Novo Nordisk | Maintains: Buy | $115 → $125 | $69.30 | +80.38% | 1 | Feb 1, 2024 | |
| MRNA Moderna | Maintains: Buy | $160 → $140 | $31.12 | +349.87% | 4 | Sep 13, 2023 | |
| BIIB Biogen | Maintains: Buy | $320 → $350 | $138.37 | +152.95% | 3 | May 11, 2023 | |
| ABBV AbbVie | Downgrades: Hold | n/a | $205.29 | - | 2 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $200 | $163.11 | +22.62% | 6 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $15.08 | - | 1 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $290 | $177.39 | +63.48% | 4 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $100 | $116.95 | -14.49% | 3 | Jun 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $270 → $295 | $230.02 | +28.25% | 4 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $4.66 | - | 3 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $135 | $167.33 | -19.32% | 5 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $33.75 | - | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $28.06 | - | 2 | Apr 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $240.33 | - | 3 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $107.62 | - | 2 | Mar 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $58.66 | - | 4 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $155 | $342.16 | -54.70% | 3 | Nov 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $216.13 | -58.36% | 1 | Sep 19, 2018 |
United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $360 → $400
Current: $306.97
Upside: +30.31%
Illumina
Aug 28, 2024
Upgrades: Buy
Price Target: $150
Current: $80.00
Upside: +87.50%
Sanofi
Jul 26, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $55.82
Upside: +7.49%
Regeneron Pharmaceuticals
Jun 25, 2024
Maintains: Buy
Price Target: $1,060 → $1,170
Current: $637.36
Upside: +83.57%
Vertex Pharmaceuticals
Jun 17, 2024
Maintains: Buy
Price Target: $465 → $550
Current: $492.69
Upside: +11.63%
AstraZeneca
May 30, 2024
Maintains: Buy
Price Target: $80 → $85
Current: $73.79
Upside: +15.19%
Novo Nordisk
Feb 1, 2024
Maintains: Buy
Price Target: $115 → $125
Current: $69.30
Upside: +80.38%
Moderna
Sep 13, 2023
Maintains: Buy
Price Target: $160 → $140
Current: $31.12
Upside: +349.87%
Biogen
May 11, 2023
Maintains: Buy
Price Target: $320 → $350
Current: $138.37
Upside: +152.95%
AbbVie
Apr 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $205.29
Upside: -
Jun 17, 2022
Maintains: Buy
Price Target: $225 → $200
Current: $163.11
Upside: +22.62%
Jan 27, 2022
Downgrades: Hold
Price Target: n/a
Current: $15.08
Upside: -
Sep 10, 2021
Maintains: Buy
Price Target: $260 → $290
Current: $177.39
Upside: +63.48%
Jun 9, 2021
Upgrades: Buy
Price Target: $100
Current: $116.95
Upside: -14.49%
May 20, 2021
Maintains: Buy
Price Target: $270 → $295
Current: $230.02
Upside: +28.25%
May 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $4.66
Upside: -
Oct 21, 2020
Upgrades: Buy
Price Target: $135
Current: $167.33
Upside: -19.32%
Sep 4, 2020
Downgrades: Hold
Price Target: n/a
Current: $33.75
Upside: -
Apr 17, 2020
Downgrades: Hold
Price Target: n/a
Current: $28.06
Upside: -
Apr 6, 2020
Downgrades: Hold
Price Target: n/a
Current: $240.33
Upside: -
Mar 24, 2020
Downgrades: Hold
Price Target: n/a
Current: $107.62
Upside: -
Oct 30, 2019
Downgrades: Hold
Price Target: n/a
Current: $58.66
Upside: -
Nov 6, 2018
Maintains: Buy
Price Target: $150 → $155
Current: $342.16
Upside: -54.70%
Sep 19, 2018
Maintains: Buy
Price Target: $85 → $90
Current: $216.13
Upside: -58.36%